Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 24

recruiting
3 973
countries
28
conditions
2 104

1 112 trials match your criteria

Hyperlipidaemia

Recruiting

Study on the Effects of Alirocumab and Drug Combination on Hyperlipidemia in Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alirocumab

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel

Meningioma

Recruiting

Study of Lutetium (177Lu) Oxodotreotide for Patients with Recurrent Meningioma Without Surgery or Radiotherapy Options

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Hepatic cirrhosis+1

Recruiting

Study on Norfloxacin for Reducing Portal Hypertension in Patients with Decompensated Cirrhosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Norfloxacin

Study on the Effects of Intracochlear Triamcinolone Acetonide for Patients with Persistent Sudden Sensorineural Hearing Loss After Unsuccessful Conservative Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Triamcinolone Acetonide

Study of Nipocalimab or IVIG for Pregnant Women at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Nipocalimab

Study on the Effectiveness and Safety of Fosmanogepix Compared to Caspofungin and Fluconazole for Adults with Candidemia or Invasive Candidiasis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Caspofungin

Myelofibrosis

Recruiting

Study of TP-3654 and Momelotinib for Patients with Intermediate or High-risk Myelofibrosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate

Study of Ziftomenib with Chemotherapy for Children with Relapsed or Refractory Acute Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant

Neoplasm malignant+1

Recruiting

Study on the Diagnostic Performance of 68Ga-ABS011 PET/CT for Patients with Metastatic Breast Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:68GA-NOTA-abscint-HER2

Study on the Safety and Effects of ION440 for Patients with MECP2 Duplication Syndrome

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ION440
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.